Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...
As a consequence of the transfer of its Jyseleca® business to Alfasigma, the revenues and costs related to Jyseleca® for the full years 2024 and 2023 are presented separately from the results of the ...
If walking is becoming difficult and physio isn’t working, cutting-edge treatments could be the next step. But which ones are ...
Garmin today announced the Descenttm G2, a rugged watch-style dive computer with features to help divers explore both their ...
CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...
Medical Device Network on MSN18h
Lineage begins study of OPC1 delivering device for spinal cord injury treatmentAn allogeneic stem cell-derived transplant, OPC1 helps restore or increase the functional activity in SCI patients. It is tailored to replace the spinal cord cells that are either ...
Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...
Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback